Billy, I understand the H1 impairment, but that was my point. So far we have :
1) $151m impairment for Hamilton (H1)
2) $115m impairment for US Rehab (H2)
3) Unspecified but "likely" impairment for Metalysis investment as per Q3 report (H2)
That's close to $300m in impairments this year. If the broker consensus is for NPAT of ~$120 million, the underlying profit before impairments would have to be in the order of $400m which I just don't see.
Like you I'm also interested in the cash situation, but the media are more likely to report the headline NPAT number. We'll find out tomorrow !
Mkango and Talaxis, page-5
Add ILU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$8.08 |
Change
0.000(0.00%) |
Mkt cap ! $3.457B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 11647 | $8.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.68 | 7995 | 9 |
View Market Depth
| Last trade - 09.56am 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$7.82 |
Change
0.000 ( 3.50 %) |
||||
| Open | High | Low | Volume | ||
| $7.82 | $7.93 | $7.79 | 12620 | ||
| Last updated 10.14am 09/05/2024 ? | |||||
| ILU (ASX) Chart |
Day chart unavailable